From September 2015 to December 2017, Ms. Brege served as managing director of Cervantes Life Science Partners, LLC, a consulting firm providing integrated business solutions to life sciences companies. She has over 20 years of executive management experience in the pharmaceutical, biotechnology, and venture capital industries. From September 2012 to July 2015, Ms. Brege was president and chief executive officer of Nodality, Inc., a life sciences company focused on innovative personalized medicine. Prior to joining Nodality in 2012, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals, Inc., a biopharmaceutical and biotherapeutics company, from 2006 to 2012, including positions as executive vice president and chief operating officer. While at Onyx, she led multiple functions, including commercialization, strategic planning, corporate development, and medical, scientific, and government affairs. Prior to Onyx, Ms. Brege was a General Partner at Red Rock Capital Management, a venture capital firm specializing in early stage financing for technology companies. Previously, Ms. Brege was senior vice president and chief financial officer at COR Therapeutics Inc. where she helped build the company from an early-stage research and development company through commercial launch of a successful cardiovascular product. Earlier in her career, she served as chief financial officer at Flextronics, Inc., and Treasurer of The Cooper Companies. She serves on the boards of directors of Acadia Pharmaceuticals Inc., Dynavax Technologies Corporation, Pacira BioSciences, Inc., Portola Pharmaceuticals, Inc., and HLS Therapeutics Inc., each of which is a public pharmaceutical company. During the past 5 years, Ms. Brege also served on the boards of directors of Delcath Systems, Inc., a pharmaceutical company, and Aratana Therapeutics, Inc., a pharmaceutical company. Ms. Brege earned her undergraduate degrees from Ohio University (Honors Tutorial College) and her M.B.A. degree from the University of Chicago.
What is Laura Brege's net worth?
The estimated net worth of Laura Brege is at least $1.12 million as of September 11th, 2025. Ms. Brege owns 15,703 shares of Mirum Pharmaceuticals stock worth more than $1,123,236 as of December 5th. This net worth evaluation does not reflect any other investments that Ms. Brege may own. Learn More about Laura Brege's net worth.
How do I contact Laura Brege?
Has Laura Brege been buying or selling shares of Mirum Pharmaceuticals?
Laura Brege has not been actively trading shares of Mirum Pharmaceuticals during the past quarter. Most recently, Laura Brege sold 17,000 shares of the business's stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $74.40, for a transaction totalling $1,264,800.00. Following the completion of the sale, the director now directly owns 15,703 shares of the company's stock, valued at $1,168,303.20. Learn More on Laura Brege's trading history.
Who are Mirum Pharmaceuticals' active insiders?
Mirum Pharmaceuticals' insider roster includes Eric Bjerkholt (CFO), Laura Brege (Director), Ian Clements (CFO), James Flynn (Major Shareholder), Michael Grey (Chairman of the Board), Patrick Heron (Director), Jolanda Howe (SVP), Lara Longpre (Chief Development Officer), Christopher Peetz (Co-Founder, CEO and Director), Joanne Quan (Chief Medical Officer), Peter Radovich (President & Chief Operating Officer), Saira Ramasastry (Director), and Pamela Vig (Insider). Learn More on Mirum Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Mirum Pharmaceuticals?
During the last twelve months, Mirum Pharmaceuticals insiders bought shares 1 times. They purchased a total of 1,335 shares worth more than $60,835.95. During the last twelve months, insiders at the sold shares 20 times. They sold a total of 251,298 shares worth more than $13,320,529.08. The most recent insider tranaction occured on September, 12th when CFO Eric Bjerkholt sold 9,578 shares worth more than $728,023.78. Insiders at Mirum Pharmaceuticals own 14.4% of the company.
Learn More about insider trades at Mirum Pharmaceuticals. Information on this page was last updated on 9/12/2025.
